UBS Group’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-225,000
Closed -$4.23M – 9934
2024
Q1
$4.23M Hold
225,000
– – ﹤0.01% 3150
2023
Q4
$3.24M Buy
+225,000
New +$3.06M ﹤0.01% 3268
2022
Q2
– Sell
-414
Closed -$14K – 10733
2022
Q1
$14K Sell
414
-5,666
-93% -$194K ﹤0.01% 7955
2021
Q4
$185K Buy
6,080
+3,748
+161% +$122K ﹤0.01% 5766
2021
Q3
$76K Buy
2,332
+239
+11% +$7.65K ﹤0.01% 6026
2021
Q2
$63K Buy
+2,093
New +$68.9K ﹤0.01% 6229

Other funds holding OGN

UBS Group's OGN Position: Q3 2026 in Review

UBS Group reduced its Organon & Co (OGN) stake by 8.4% in Q3 2026, selling an estimated $5.53M and leaving 4,450,913 shares worth $61M. The position accounts for 0.01% of the portfolio, ranked #1510.

UBS Group first reported a position in OGN in Q2 2021 and has held it in 22 quarters since. The position peaked at $65.8M in Q2 2026. 359 funds tracked by Wall St. Rank hold OGN as of Q3 2026.

  • UBS Group held 4,450,913 shares of Organon & Co worth $61M as of Q3 2026.
  • UBS Group sold 405,616 Organon & Co shares in Q3 2026, an estimated $5.53M.
  • Organon & Co made up 0.01% of UBS Group's portfolio in Q3 2026, its #1510 holding.
  • UBS Group first reported a position in Organon & Co in Q2 2021 and has held it in 22 quarters since.
  • UBS Group's Organon & Co position peaked at $65.8M in Q2 2026.
  • 359 funds tracked by Wall St. Rank held Organon & Co as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.